PHASE 3, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZS-9: SUBGROUP ANALYSIS STRATIFIED BY BASELINE SERUM POTASSIUM LEVELS

被引：0

作者：

Singh, Bhupinder ^{[1
]}

Rasmussen, Henrik S. ^{[2
]}

Lavin, Phillip T. ^{[3
]}

Yang, Alex ^{[4
]}

Roger, Simon D. ^{[5
]}

机构：

[1] Apex Res Riverside, Riverside, AZ USA

[2] ZS Pharma Inc, Coppell, TX USA

[3] Boston Biostat Res Fdn, Framingham, MA USA

[4] Xelay Acumen Inc, Belmont, CA USA

[5] Renal Res, Gosford, Australia

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2014年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

SP321

引用

页码：178 / 179

页数：2

共 50 条

[1] EFFICACY OF ZS-9 IN PATIENTS RECEIVING RAAS THERAPY: A SUBGROUP ANALYSIS OF A PHASE 3 MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Roger, Simon D.
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
El-Shahawy, Mohamed A.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 180 - 180
[2] ACUTE-PHASE EFFICACY IN A PHASE 3 MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZS-9 FOR HYPERKALAEMIA
El-Shahawy, Mohamed A.
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
Packham, David K.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 178 - 178
[3] SAFETY AND TOLERABILITY OF ZS-9 IN A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH HYPERKALAEMIA
Packham, David K.
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
Qunibi, Wajeh Y.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 184 - 184
[4] INDIVIDUALIZING ZS-9 DOSING FOR SERUM POTASSIUM REDUCTION IN HYPERKALEMIC PATIENTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Lavin, Philip T.
Yang, Alex
Singh, Bhupinder
Rasmussen, Jacob
Stavros, Fiona
Winger, Roland
Kovalsky, Matthew P.
Sorrells, Brent
Rasmussen, Henrik S.
AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (05) : A119 - A119
[5] Maintenance of normal serum K+ with ZS-9 once daily in patients with CHF: subgroup analysis of a phase 3 multicenter, randomised, double-blind, placebo-controlled trial of patients with hyperkalaemia
El-Shahawy, M. A.
Singh, B.
Rasmussen, H. S.
Lavin, P. T.
Yang, A.
Qunibi, W.
EUROPEAN HEART JOURNAL, 2014, 35 : 722 - 722
[6] ACUTE-PHASE EFFICACY OF ZS-9 IN PATIENTS WITH BASELINE SERUM POTASSIUM LEVELS ABOVE 5.5 MECVL: ANALYSIS FROM A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL
El-Shahawy, Mohamed
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
Packham, David K.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A878 - A878
[7] EXTENDED EFFICACY OF ZS-9 ONCE-DAILY IN A PHASE 3 MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH HYPERKALAEMIA
Roger, Simon D.
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
Qunibi, Wajeh Y.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 182 - 182
[8] Achievement of Normokalemia with ZS-9 Across Subgroups in a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Hyperkalemia
Singh, Bhupinder
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
El-Shahawy, Mohamed A.
HYPERTENSION, 2014, 64
[9] Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Once-Daily ZS-9 for Treatment of Hyperkalemia: Maintenance of Serum K+ in Subgroup Analysis of Patients on RAAS Therapy
Singh, Bhupinder
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
Roger, Simon D.
HYPERTENSION, 2014, 64
[10] Maintenance of Normokalemia with ZS-9 Once Daily in CHF Patients on RAAS Inhibitors: Subgroup Analysis of a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Hyperkalemia
EI-Shahawy, Mohamed A.
Singh, Bhupinder
Rasmussen, Henrik S.
Lavin, Philip T.
Yang, Alex
Qunibi, Wajeh
HYPERTENSION, 2014, 64

← 1 2 3 4 5 →